Reformulation Is Much Easier Than Developing A New Injectable Drug Product. So Why Aren't We Doing It More?

An interview with Dr. Tom Tice, Evonik Health Care

We all know about the significant financial costs and clinical risks involved in bringing a new injectable drug product to market.  So why isn’t reformulation or repurposing being used more often to meet these challenges?  In this interview with Dr. Tom Tice, one of the world’s leading experts on extended release injectables and implants, we review current and emerging areas of reformulation focus, and some best practices to get your strategy right.